264208-60-8

Basic information

• Product Name: ethyl 4-((1-Methylpiperidin-4-yl)Methoxy)-3-Methoxybenzoate
• Synonyms: ethyl 4-((1-Methylpiperidin-4-yl)Methoxy)-3-Methoxybenzoate;Ethyl 3-methoxy-4-((1-methylpiperidin-4-yl)methoxy)benzoate;4-((1-Methylpiperidin-4-yl)Methoxy)-3-Methoxybenzoate
• CAS NO: 264208-60-8
• Molecular Formula: C₁₇H₂₅NO₄
• Molecular Weight: 307.3847
• Mol File: 264208-60-8.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 413.0±25.0 °C(Predicted)
• Appearance: /
• Density: 1.077±0.06 g/cm3(Predicted)
• PKA: 9.07±0.10(Predicted)
• CAS DataBase Reference: ethyl 4-((1-Methylpiperidin-4-yl)Methoxy)-3-Methoxybenzoate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 4-((1-Methylpiperidin-4-yl)Methoxy)-3-Methoxybenzoate(264208-60-8)
• EPA Substance Registry System: ethyl 4-((1-Methylpiperidin-4-yl)Methoxy)-3-Methoxybenzoate(264208-60-8)

Safety Data

• Hazardous Substances Data: 264208-60-8(Hazardous Substances Data)

Usage

General Description

Ethyl 4-((1-Methylpiperidin-4-yl)Methoxy)-3-Methoxybenzoate is a chemical compound with the molecular formula C19H27NO4. It is a ester of 4-((1-methylpiperidin-4-yl)methoxy)-3-methoxybenzoic acid and ethyl alcohol. ethyl 4-((1-Methylpiperidin-4-yl)Methoxy)-3-Methoxybenzoate is often used in the field of pharmaceuticals and chemical research, and it may have various pharmacological properties and uses. It is important to handle this compound with care and to follow proper safety protocols and precautions when working with it.

Upstream product

• 264208-58-4 ethyl 4-(1-(tert-butoxycarbonyl)piperidin-4-ylmethoxy)-3-methoxybenzoate 
• 50-00-0 formaldehyd 
• 835633-50-6 N-formyl-4-piperidinemethanol 

Downstream Products

• 264208-63-1 ethyl 3-methoxy-4-(1-methylpiperidin-4-ylmethoxy)-6-nitrobenzoate 

Relevant articles and documents

Implant he loni intermediate compound and its preparation method

The invention discloses a vandetanib intermediate compound and a preparation method thereof. The preparation method of the above compound I is characterized in that a compound V is reduced in an organic solvent under the action of boron hydride and iodine. The preparation method has the advantages of mild reaction condition, simple operation, low cost, and suitableness for industrial production.

Quinazoline derivatives

The invention concerns quinazoline derivatives of Formula (I) wherein Q1includes a quinazoline ring optionally substituted with a group such as halogeno, trifluoromethyl and cyano, or a group of the formula: Q3—X1— wherein X1includes a direct bond and O and Q3includes aryl, aryl-(1-6C)alkyl, heterocyclyl and heterocyclyl-(1-6C)alkyl; each of R2and R3is hydrogen or (1-6C)alkyl; Z includes O, S and NH; and Q2includes aryl and aryl-(1-3C)alkyl or a pharmaceutically-acceptable salt thereof; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the prevention or treatment of T cell mediated diseases or medical conditions in a warm-blooded animal.